Breast Reconstruction Use and Impact on Surgical and Oncologic Outcomes Amongst Inflammatory Breast Cancer Patients-A Systematic Review.
Ananya Gopika NairGary Tsun Yin KoJohn Laurie SempleDavid Wai LimPublished in: Current oncology (Toronto, Ont.) (2023)
Breast reconstruction is generally discouraged in women with inflammatory breast cancer (IBC) due to concerns with recurrence and poor long-term survival. We aim to determine contemporary trends and predictors of breast reconstruction and its impact on oncologic outcomes among women with IBC. A systematic literature review for all studies published up to 15 September 2022 was conducted via MEDLINE, Embase, and the Cochrane Library. Studies comparing women diagnosed with IBC undergoing a mastectomy with or without breast reconstruction were evaluated. The initial search yielded 225 studies, of which nine retrospective cohort studies, reporting 2781 cases of breast reconstruction in 29,058 women with IBC, were included. In the past two decades, immediate reconstruction rates have doubled. Younger age, higher income (>USD 25,000), private insurance, metropolitan residence, and bilateral mastectomy were associated with immediate reconstruction. No significant difference was found in overall survival, breast cancer-specific survival or recurrence rates between women undergoing versus not undergoing (immediate or delayed) reconstruction. There is a paucity of data on delayed breast reconstruction following IBC. Immediate breast reconstruction may be a consideration for select patients with IBC, although prospective data is needed to clarify its safety.
Keyphrases
- breast reconstruction
- free survival
- oxidative stress
- healthcare
- polycystic ovary syndrome
- big data
- physical activity
- case control
- electronic health record
- mental health
- prostate cancer
- machine learning
- systematic review
- randomized controlled trial
- radical prostatectomy
- young adults
- health insurance
- pregnancy outcomes
- pregnant women
- cross sectional
- deep learning
- adverse drug
- drug induced